Prospects for gene therapy for inherited cardiomyopathies

Area of Science:

• Cardiovascular Genetics
• Molecular Cardiology
• Genetic Medicine

Background:

• Genetic cardiomyopathies, including dilated and hypertrophic forms, result from defects in cytoskeletal and sarcomeric proteins.
• Genetic heterogeneity exists, but a common pathway involves protein dysfunction.
• Identifying causative genes aids in developing targeted therapies.

Purpose of the Study:

• To review the identification of gene defects in cardiomyopathies.
• To discuss the potential of gene therapy for treating these cardiovascular diseases.
• To address challenges and concerns associated with gene therapy vectors, especially adenoviruses.

Main Methods:

• Literature review of genetic studies in cardiomyopathies.
• Analysis of gene mutations and their functional consequences.
• Evaluation of gene therapy strategies and vector technologies.

Main Results:

• Specific genes linked to X-linked/autosomal dominant dilated cardiomyopathy and hypertrophic cardiomyopathy identified.
• Defects in cytoskeletal proteins cause dilated cardiomyopathy; sarcomeric proteins cause hypertrophic cardiomyopathy.
• Gene therapy approaches show promise but face hurdles in human translation.

Conclusions:

• Understanding genetic underpinnings is crucial for cardiomyopathy treatment development.
• Gene therapy holds potential but requires overcoming vector-related issues and ensuring safety.
• Adenovirus vectors warrant caution due to their association with acquired dilated cardiomyopathy.